Autoinflammatory & rare systemic diseases
Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort
Authors' conclusion
Our results show that IL-18 can discriminate Still's disease from other SAID, and free IL-18 levels may be relevant to assess response to therapy in these patients.
Study context
- Population
- Patients with active SAID (monogenic and genetically undiagnosed) from different European countries (ImmunAID cohort)sera analysed
- Participants
- 53 / 220 / 49
- Comparison
- Serum IL-1β, IL-18, IL-1Ra, IL-18BP and IFN-γ across SAID and non-inflammatory controls
- mSAIDn = 53
- Genetically undiagnosed SAID (guSAID)n = 220
- Controlsn = 49reference
- Outcome
- Diagnostic value of serum IL-1β, IL-18, IL-1Ra, IL-18BP and IFN-γ in SAID
Methodological detailsmultinational European cohort
- Multinational European cohort
Performance
As reported in the abstract
Diagnosis of Still's disease
Total IL-18 the most sensitive and specific marker for Still's disease diagnosis (ROC analysis), AUC
0.91
Further findings
Correlation of IL-18 with ferritin
- Positive correlation between IL-18 and ferritin
Free IL-18 after treatment in Still's disease (n=10 with second blood collection)
- Significant decrease in serum free IL-18 after treatment
Original publication
Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort. RMD Open. Published 7 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →